Wezlana™ ,
Ustekinumab-auub
Disease
Crohn's disease
,
Ulcerative colitis
,
Drug Class
Biologics/Biosimilars
Delivery Method
IV
or
Injection
or
Brand name:
Wezlana™
(This drug is a biosimilar to Stelara®)
,Drug name:
Ustekinumab-auub
Drug type
Interleukin-12 and -23 Antagonist
Recommendations for pregnancy
Limited human data; No adverse effects or risks in animal studies.
Recommendations for breastfeeding
No human data.
Most common side effects
Common side effects include upper respiratory infections, headache, tiredness, itching, vomiting, vaginal yeast infections, urinary tract infections, redness at the injection site
Other
Rare side effects include risk of serious infections, risk of malignancy, hypersensitivity reactions (anaphylaxis), Posterior Reversible Encephalopathy Syndrome (PRES), and non infectious pneumonia. Wezlana™ is an FDA approved interchangeable biosimilar to Stelara® (ustekinumab).
Learn more about
Biologics/Biosimilars